IFM Therapeutics develops first-in-class small molecules that precisely target the innate immune system to regulate immune responses in patients with inflammation-driven diseases and cancer. Their approach addresses the need for effective biological treatments by advancing novel drug candidates from discovery to clinical trials.
Funding
$55.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many inflammation-driven diseases and cancers lack effective treatments that can precisely regulate the innate immune system. Current biological treatments often have broad effects, leading to off-target effects and suboptimal patient outcomes. There is a need for novel therapeutics that can selectively modulate immune responses to address the underlying causes of these diseases.
Solution
IFM Therapeutics develops first-in-class small molecule drugs designed to precisely target and modulate the innate immune system. Their approach focuses on controlling or enhancing immune responses across various disease indications, including inflammation-driven diseases and cancer. By selectively targeting key components of the innate immune system, IFM aims to develop transformative medicines that offer improved efficacy and reduced off-target effects compared to existing treatments. The company has advanced multiple novel programs from discovery through clinical trials, demonstrating a track record of translating innovative research into potential therapeutic candidates.
Target Audience
The primary target audience includes patients suffering from inflammation-driven diseases and various cancers, as well as pharmaceutical companies seeking novel therapeutic candidates for these conditions.
Features
- Focus on small molecule agonists and antagonists of innate immune pathways
- Programs targeting NLRP3, STING, and cGAS
- Advancing novel drug candidates from discovery to first-in-human studies
- Development of medicines to precisely control or enhance immune responses across disease indications